Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 218Thoracic 73Head & Neck 26Other solid neoplasm 14Gynecologic 14Lymphoid 10Breast 9Tumor-Agnostic 7CNS 6Sarcoma 4Genitourinary 4Endocrine 3Other neoplasm 2NET 2Dermatologic 2Myeloid 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1Lymphohistiocytosis, Hemophagocytic 1

Interventions

Cyclophosphamide 261fludarabine phosphate 233Azacitidine 182fludarabine 181Busulfan 176Cytarabine 155Imatinib Mesylate 152Mycophenolic Acid 148Tacrolimus 146Whole-Body Irradiation 142Peripheral Blood Stem Cell Transplantation 140Cyclosporine 110Antilymphocyte Serum 108Melphalan 107Methotrexate 105Filgrastim 101Decitabine 98nilotinib 94venetoclax 79ruxolitinib 79Dasatinib 68Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 63Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
sintilimab × Myeloid × Clear all
NCT05008666 2021-08-17

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Sun Yat-sen University

Phase 2 Unknown
37 enrolled
LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡